



ASX Announcement

20 December 2019

DARRT-1 Clinical Data Webinar

WEBINAR HIGHLIGHTS

- **DARRT program delivers strong anti-cancer response in 47% of men with late-stage prostate cancer**
 - **Independent oncologist confirms significance of high response rate**
 - **Promising new therapy for major unmet need in prostate cancer**
 - **Planned adaptive design Phase 2 study expected to be final step to gaining marketing approval**
-

SYDNEY, December 20, 2019: Noxopharm (NOX:ASX) releases a webinar containing further details on its DARRT-1 study clinical data read-out, along with a commentary from prominent Australian medical oncologist, Professor Paul de Souza, Head of School and Dean of Medicine at University of Wollongong.

The webinar can be found at the following link prior to posting on the Noxopharm website.

<https://www.finnewsnetwork.com.au/MediaCenter/MediaCenterMobile.aspx?Site=FNN1731>
.....

About Noxopharm

Noxopharm is a clinical-stage Australian drug development company with offices in Sydney and New York. The Company has a primary focus on the development of Veyonda® and is the major shareholder in Nyrada Inc, a spin-off company developing a pipeline of non-oncology drugs. www.noxopharm.com

Investor & Corporate Enquiries:

Dr Graham Kelly
M: 0429 854 390
E: graham.kelly@noxopharm.com

Company Secretary:

David Franks
T: +61 2 9299 9690
E: David.Franks@automicgroup.com.au

Media queries:

Catherine Strong
Citadel-MAGNUS
T: 02 8234 0111
E: cstrong@citadelmagnus.com

Suite 3, Level 4, 828 Pacific Highway, Gordon NSW 2072

**Forward Looking Statements**

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. No representation, warranty or assurance (express or implied) is given or made by Noxopharm that the forward-looking statements contained in this announcement are accurate and undue reliance should not be placed upon such statements.

Authorisation: This release was authorised by Graham Kelly (Noxopharm CEO and Executive Chairman) on behalf of the Board of Directors.